Ceftizoxime was evaluated in the treatment of 18 patients (6 adults and 12 children) with bacterial meningitis. In seven patients Haemophilus influenzae was the causative agent, in three Neisseria meningitidis, in five Streptococcus pneumoniae, and in one each a-streptococcus and Escherichia coli; one case was culture negative. Ceftizoxime was administered intravenously in doses of 200 mg/kg per day. Clinical response was appropriate in all patients with a mean time of defervescence of 3.7 days, and sterile cerebrospinal fluid was obtained from all patients at 24 to 36 h after initiation of therapy. The mean concentration of ceftizoxime in 46 cerebrospinal fluid samples obtained during therapy was 8.53 ,g/ml (range, <0.5 to 29.0 ,ug/ml). Ceftizoxime concentrations in cerebrospinal fluid samples were ten-to several hundredfold the bactericidal concentrations of the pathogens isolated from the cerebrospinal fluid. Ceftizoxime penetrates the meninges well during acute infection and appears to be an excellent candidate antibiotic in the treatment of bacterial meningitis.
meningococci are <0.12 and '0.01 jig/ml, respectively (1, 6, 7) . Haemophilus influenzae, including beta-lactamase-producing isolates, are uniformly inhibited by concentrations of -0. 1 Rg of ceftizoxime per ml (1, 10) . In addition, ceftizoxime is very active against many enteric organisms and nosocomial pathogens (1) .
In preliminary studies of ceftizoxime in bacterial meningitis, a mean concentration in cerebrospinal fluid (CSF) of 4.9 ,ug of ceftizoxime per ml was achieved after administration of single doses of 30 mg/kg intravenously, and mean CSF-toserum ratios were 22.5% (2) . Thus, the demonstrated activity against meningeal pathogens and preliminary results of probable therapeutic concentrations in CSF warranted further study of the achievable concentrations of ceftizoxime in CSF during treatment and its efficacy and safety in patients with meningeal infections.
MATERIALS AND METHODS
Patients. A total of 23 consecutive patients admitted to the Communicable Disease Service of the Los Angeles CountyUniversity of Southern California Medical Center, with a diagnosis of suspected bacterial meningitis, were enrolled in the study. One additional patient with H. influenzae meningitis was enrolled after unsuccessful therapy with trimethoprim-sulfamethoxazole. Informed written consent was obtained from each patient, parent, or appropriate guardian before enrollment. Patients were excluded from therapy if: (i) they were allergic to penicillins or cephalosporins; (ii) there was a requirement for concurrent antimicrobial therapy; (iii) there was the presence of significant underlying disease that would confound analysis of ceftizoxime therapy; (iv) the subsequent course proved to be due to a nonbacterial etiology; or (v) if death occurred within the first 12 h of treatment.
The diagnosis of meningitis was confirmed in all patients with a positive CSF or blood culture in association with a consistent clinical presentation and CSF changes for acute bacterial infection. A single patient was included who had negative blood and CSF cultures but had gram-positive diplococci (i.e., "purulent unknown") on CSF smear. In addition, all patients satisfied two or more of the following criteria: (i) a predominately polymorphonuclear CSF leukocyte (WBC) pleocytosis (>500 cells per mm3), (ii) a protein level of 2100 mg/100 ml, or (iii) a glucose level of --50% of a simultaneously obtained serum glucose value.
Administration of ceftizoxime. Ceftizoxime was administered to all patients in a daily dose of 200 mg/kg divided into six equal doses (every 4 h); maximal single doses of 2 g (or 12.0 g daily) were not exceeded. Each ceftizoxime dose was administered intravenously in a total volume of 10 to 25 ml over a mean of 12 min (range, 5 to 30 min). Patients were treated until they were afebrile for 5 days or for a minimum duration of 10 days for patients with infections due to Neisseria meningitidis and Streptococcus pneumoniae and 14 days for those with H. influenzae infection. Patients were followed daily to assess clinical response. Lumbar punctures were performed on day 1 (i.e., 24 to 36 h after the initiation of therapy), 3, 7 or 10, and 14 of ceftizoxime therapy.
CSF studies. The mean duration of fever after initiation of ceftizoxime therapy was 3.7 days (range, 1 to 14 days). Two patients had prolonged fevers. One patient with H. influenzae meningitis and associated otitis media, cholesteatoma, and cerebellar abscess had a fever for 14 days. The second patient with N. meningitidis infection experienced severe skin necrosis due to purpuric infarcts and had 7 days of fever. Significant neurological residua at the end of therapy were apparent in two patients, both of whom had defined neurological complications during hospitalization. A child with H. influenzae meningitis previously noted to have infection with an ampicillin-, chloramphenicol-, trimethoprim-sulfamethoxazole-resistant isolate had a subdural abscess. This child was taken to surgery after 8 days of ceftizoxime therapy where the empyema was drained. A second child had a H. influenzae infection and a cerebellar pontine abscess that was drained on day 13 bND, Nondetectable (<0.5 Ftg/ml). specimens were culture negative. Of six CSF specimens obtained at 36 h, all were Gram stain negative, as was a single CSF specimen obtained at 48 h. A sample of subdural empyema fluid yielded H. influenzae on culture at 24 and 48 h after the initiation of therapy, but it was subsequently negative at cultures obtained at 96 h.
Ceftizoxime concentrations in CSF and serum. A total of 46 CSF samples were collected within 30 to 420 min (mean, 133 min) after doses were administered during the course of bacterial meningitis. In 40 of these samples, a paired serum was available for analysis. The time of obtaining CSF after administration of the dose, and the concomitantly measured concentration in CSF and serum for each sample is displayed in Table 2 . The mean concentration in CSF was 8.53 ,ug of ceftizoxime per ml (range, <0.5 to 29 ,ug/ml). Only two CSF samples had nondetectable levels of ceftizoxime, and both of these samples were collected after 11 days of therapy. The median CSF/serum ratio was 22.6% (range, 0 to 150%o). A single subdural fluid concentration was 42 ,ug/ml. The concentration of drug in CSF did not correlate with the WBC count or glucose concentration in CSF (data not shown) but a trend for higher concentrations in CSF was observed in those CSF samples with higher protein concentrations or in those CSF samples obtained during the early days of treatment (Fig. 1) . Of those patients with CSF collected at the time of a normal protein concentration (<49 mg/dl) the mean level in CSF was 4.47 ,ug/ml (n = 10), (8) , ceftazidime (9) , and ceftriaxone (5 In the current studies, 18 patients with meningitis caused by pathogens acquired in the community were treated successfully with ceftizoxime. All patients responded well clinically and yielded negative cultures after 24 to 48 h of therapy. MBCs of ceftizoxime against all recovered bacterial isolates were well below the measured concentrations of the antibiotic in the spinal fluid. Thus, the average concentrations in CSF achieved in this study were ten-to several hundredfold the inhibitory concentrations for S. pneumoniae, H. influenzae, and N. meningitidis. Under the conditions of repeated intravenous doses (30 mg/kg per dose) given at 4-h intervals in the presence inflamed meninges, ceftizoxime penetrated the meninges well, with mean concentrations in CSF of 8.53 ,ug/ml and median CSF/serum ratios of 22.6%. The mean duration offever after initiation of therapy was 3.7 days, and the incidence of neurological complications and side effects related to ceftizoxime were comparable to those which might be expected with conventional drug regimens.
The high level of activity of ceftizoxime against gramnegative pathogens and an acceptable activity against grampositive pathogens makes this antibiotic an excellent candidate for treatment of community-acquired bacterial meningitis as well as nosocomially acquired meningeal infections. Further studies of ceftizoxime in bacterial meningitis are indicated, including comparative studies against current regimens and broad spectrum cephalosporins.
